Table 1 The baseline characteristics of DC patients with significant coagulopathy in the FFP transfusion group and conventional group before and after PSM.

From: Efficacy of fresh frozen plasma transfusion in decompensated cirrhosis patients with coagulopathy admitted to ICU: a retrospective cohort study from MIMIC-IV database

Variable

Before match

After match

FFP transfusion group (n = 317)

Conventional group (n = 376)

P-value

FFP transfusion group (n = 233)

Conventional group (n = 233)

P-value

Demographic data

 Age (year)

56.03 ± 10.78

59.51 ± 11.63

 < 0.01*

56.29 ± 10.86

57.03 ± 10.66

0.46

 Gender

  

0.22

  

1.00

  Male

200 (63.09%)

220 (58.51%)

 

145 (62.23%)

145 (62.23%)

 

  Female

117 (36.91%)

156 (41.49%)

 

88 (37.77%)

88 (37.77%)

 

Score system

 MELD score

33.00 (27.00–40.00)

28.00 (22.75–35.00)

 < 0.01*

32.00 (26.00–38.00)

31.00 (26.00–38.00)

0.49

 CLIF-SOFA score

13.00 (10.00–15.00)

10.00 (7.00–13.00)

 < 0.01*

12.00 (10.00–15.00)

11.00 (8.00–14.00)

0.07

Laboratory data

 PLT (109/L)

56.00 (40.00–85.00)

66.00(40.50–108.50)

 < 0.01*

61.00 (42.00–96.00)

64.00 (40.00–101.00)

0.83

 AST (U/L)

89.5 (48.00–343.50)

83.0 (43.00–146.00)

 < 0.01*

85.0 (47.00–308.00)

91.0 (46.00–177.00)

0.47

 ALT (U/L)

41.0 (23.00–102.75)

37.5 (21.00–66.25)

0.03*

40.0 (22.00–102.00)

40.0 (23.00–77.00)

0.89

 PT (sec)

27.40 (23.00–35.10)

24.10 (20.70–30.98)

 < 0.01*

26.70 (22.40–32.90)

26.00 (21.70–33.00)

0.21

 APTT (sec)

54.95 (44.62–79.97)

48.35 (38.98–67.12)

 < 0.01*

53.70 (43.10–77.30)

51.40 (41.40–70.60)

0.07

 INR

2.60 (2.20–3.30)

2.30 (1.90–2.90)

 < 0.01*

2.50 (2.10–3.30)

2.40 (2.00–3.10)

0.15

Anticoagulants use

292 (92.11%)

312 (82.98%)

 < 0.01*

211 (90.56%)

205 (87.98%)

0.37

Bleeding

196 (61.83%)

153 (40.69%)

 < 0.01*

128 (54.94%)

113 (48.50%)

0.16

Comorbidities

 Hypertension

126 (39.75%)

176 (46.81%)

0.06

94 (40.34%)

99 (42.49%)

0.64

 Diabetes

85 (26.81%)

108 (28.72%)

0.58

60 (25.75%)

63 (27.04%)

0.75

 CPOD

61 (19.24%)

81 (21.54%)

0.46

48 (20.60%)

50 (21.46%)

0.82

 Renal disease

68 (21.45%)

97 (25.80%)

0.18

51 (21.89%)

53 (22.75%)

0.82

  1. Results are expressed as mean ± SD, median (Q1-Q3), or n (%). *P < 0.05. FFP, fresh frozen plasma; MELD, the model for end-stage liver disease score; SOFA, the sequential organ failure assessment score; PLT, platelet; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PT, prothrombin time; APTT, activated partial thromboplastin time; INR, international normalization ratio; COPD, chronic obstructive pulmonary disease.
Back to article page